Kodiak Sciences Inc (FRA:K27)
€ 3.546 0.072 (2.07%) Market Cap: 211.94 Mil Enterprise Value: 80.00 Mil PE Ratio: 0 PB Ratio: 0.96 GF Score: 37/100

Kodiak Sciences Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 11:40PM GMT
Release Date Price: €8.66 (+4.82%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Thanks, everyone, for joining us for the last session of the third day of our conference. I'm pleased to be joined by Victor Perlroth, CEO of Kodiak Sciences. Thank you so much, Victor.

Victor Perlroth
Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President

Thanks a lot, Andrea. Can you hear me?

Questions & Answers

Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Yes. So maybe we can start. We're at an exciting time for Kodiak. We're sitting in front of 4 Phase III trials that are coming, starting in July. Maybe help frame -- maybe let's take a step back actually. Let's talk about your antibody platform, and how is it uniquely positioned to address this idea of durability?

Victor Perlroth
Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President

Right. Well, that's a good question because we start with the science of the design and then

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot